Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study.

Saved in:
Bibliographic Details
Title: Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study.
Authors: Bernstein JA; Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML#563, Cincinnati, OH, 45267-0563, USA. bernstja@ucmail.uc.edu.; Advanced Allergy Services LLC, Cincinnati, OH, USA. bernstja@ucmail.uc.edu.; Bernstein Clinical Research Center, Cincinnati, OH, USA. bernstja@ucmail.uc.edu., Betschel SD; Division of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, Toronto, ON, Canada., Busse PJ; Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Banerji A; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Wedner HJ; Division of Allergy & Immunology, Washington University School of Medicine in St Louis, St Louis, MO, USA., Manning M; Allergy, Asthma & Immunology Associates, Ltd., Scottsdale, AZ, USA., Zaragoza-Urdaz RH; University of Puerto Rico School of Medicine and University Pediatric Hospital, San Juan, Puerto Rico., Anderson J; AllerVie Health, Birmingham, AL, USA., Gagnon R; Clinique Spécialisée en Allergie de la Capitale, Quebec, QC, Canada., Baptist AP; Division of Allergy and Immunology, Henry Ford Health, Detroit, MI, USA., Soteres D; Asthma & Allergy Associates, P.C., Colorado Springs, CO, USA., Lumry WR; Allergy and Asthma Research Associates, Dallas, TX, USA., Craig T; Allergy, Asthma and Immunology, Departments of Medicine, Pediatrics and Biomedical Sciences, ACARE International Hereditary Angioedema Resource Center, Penn State University, Hershey, PA, USA.; Vinmec International Hospital, Times City, Hanoi, Vietnam., Petroni D; Seattle Allergy and Asthma Research Institute, Seattle, WA, USA., Hsu FI; Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Nova Estepan D; Takeda Development Center Americas, Inc., Lexington, MA, USA., Juethner S; Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA., Watt M; Takeda Development Center Americas, Inc., Lexington, MA, USA., Khutoryansky N; Takeda Development Center Americas, Inc., Lexington, MA, USA., Zuraw BL; Division of Allergy & Immunology, University of California San Diego, La Jolla, CA, USA.
Corporate Authors: EMPOWER Investigators
Source: Advances in therapy [Adv Ther] 2025 Aug; Vol. 42 (8), pp. 3882-3901. Date of Electronic Publication: 2025 Jun 12.
Publication Type: Journal Article; Clinical Trial, Phase IV; Multicenter Study
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1865-8652
DOI:10.1007/s12325-025-03226-3